Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma
- PMID: 2847992
- DOI: 10.1007/BF00175401
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma
Abstract
Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.
References
MeSH terms
Substances
LinkOut - more resources
Medical